文献速递慢性肾脏病水电解质与酸碱

短期氯化钾补充对慢性肾脏病患者的影响

Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.
PubMed 文献 · J Am Soc Nephrol · 2022-05-24

该研究为一项临床试验导入期的预设分析,纳入191例慢性肾脏病G3b-4期患者,每日补充40 mmol氯化钾持续2周。结果显示补钾显著增加尿钾排泄、血钾和血浆醛固酮,并升高血氯、降低血碳酸氢盐和尿pH,但未显著影响尿钠、血浆肾素、血压、估算肾小球滤过率或白蛋白尿。21例(11%)发生高钾血症,多为年龄较大且基线血钾较高者。

要点

  • 慢性肾脏病G3b-4期患者每日补充40 mmol氯化钾2周,血钾平均升高0.4 mmol/L。
  • 补钾后尿钾排泄、血钾、血浆醛固酮、血氯升高,血碳酸氢盐和尿pH降低。
  • 21例(11%)发生高钾血症,年龄较大和基线血钾较高者风险更高。

核心结论

  • 在慢性肾脏病G3b-4期患者中,通过氯化钾补充将膳食钾摄入增至推荐水平可使血钾升高0.4 mmol/L。
  • 这可能使年龄较大或基线血钾较高的患者发生高钾血症。
  • 需要较长期研究评估心肾保护是否超过高钾血症风险。

研究设计与样本

  • 该研究为一项临床试验导入期的预设分析。
  • 共纳入191例患者,年龄68±11岁,男性占74%,欧洲血统占86%,估算肾小球滤过率31±9 ml/min per 1.73 m2,使用肾素-血管紧张素系统抑制剂者占83%,糖尿病患者占38%。
  • 患者每日接受40 mmol氯化钾治疗,持续2周。

主要发现

  • 氯化钾补充显著增加尿钾排泄(从72±24增至107±29 mmol/天)、血钾(从4.3±0.5增至4.7±0.6 mmol/L)和血浆醛固酮(从281 [198-431]增至351 [241-494] ng/L)。
  • 氯化钾补充对尿钠排泄、血浆肾素、血压、估算肾小球滤过率或白蛋白尿无显著影响。
  • 氯化钾补充升高血氯(从104±3增至105±4 mmol/L),降低血碳酸氢盐(从24.5±3.4降至23.7±3.5 mmol/L)和尿pH(均P<0.001),但未改变尿铵排泄。
  • 共21例参与者(11%)发生高钾血症(血钾5.9±0.4 mmol/L),这些患者年龄较大且基线血钾较高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies suggest that adequate dietary potassium intake (90-120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown. METHODS: This is a prespecified analysis of the run-in phase of a clinical trial in which 191 patients (age 68±11 years, 74% males, 86% European ancestry, eGFR 31±9 ml/min per 1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol potassium chloride (KCl) per day for 2 weeks. RESULTS: KCl supplementation significantly increased urinary potassium excretion (72±24 to 107±29 mmol/day), plasma potassium (4.3±0.5 to 4.7±0.6 mmol/L), and plasma aldosterone (281 [198-431] to 351 [241-494] ng/L), but had no significant effect on urinary sodium excretion, plasma renin, BP, eGFR, or albuminuria. Furthermore, KCl supplementation increased plasma chloride (104±3 to 105±4 mmol/L) and reduced plasma bicarbonate (24.5±3.4 to 23.7±3.5 mmol/L) and urine pH (all P<0.001), but did not change urinary ammonium excretion. In total, 21 participants (11%) developed hyperkalemia (plasma potassium 5.9±0.4 mmol/L). They were older and had higher baseline plasma potassium. CONCLUSIONS: In patients with CKD stage G3b-4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.Clinical trial number: NCT03253172.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gritter M, Wouda RD, Yeung SMH, et al. Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD. J Am Soc Nephrol. 2022. PMID: 35609996. doi:10.1681/ASN.2022020147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。